These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
469 related articles for article (PubMed ID: 24726140)
1. CTHRC1 acts as a prognostic factor and promotes invasiveness of gastrointestinal stromal tumors by activating Wnt/PCP-Rho signaling. Ma MZ; Zhuang C; Yang XM; Zhang ZZ; Ma H; Zhang WM; You H; Qin W; Gu J; Yang S; Cao H; Zhang ZG Neoplasia; 2014 Mar; 16(3):265-78, 278.e1-13. PubMed ID: 24726140 [TBL] [Abstract][Full Text] [Related]
2. CTHRC1 overexpression promotes cervical carcinoma progression by activating the Wnt/PCP signaling pathway. Zheng M; Zhou Q; Liu X; Wang C; Liu G Oncol Rep; 2019 Mar; 41(3):1531-1538. PubMed ID: 30628714 [TBL] [Abstract][Full Text] [Related]
3. CTHRC1 promotes human colorectal cancer cell proliferation and invasiveness by activating Wnt/PCP signaling. Yang XM; You HY; Li Q; Ma H; Wang YH; Zhang YL; Zhu L; Nie HZ; Qin WX; Zhang ZG; Li J Int J Clin Exp Pathol; 2015; 8(10):12793-801. PubMed ID: 26722469 [TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal stromal tumors (GIST): a single center experience. Kostka R; Gürlich R; Koldová L Acta Chir Belg; 2012 Jan; 112(1):33-9. PubMed ID: 22442907 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome. Zhao WY; Xu J; Wang M; Zhang ZZ; Tu L; Wang CJ; Cao H; Zhang ZG BMC Gastroenterol; 2014 Jun; 14():105. PubMed ID: 24906683 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of malignancy using Ki-67, p53, EGFR and COX-2 expressions in gastrointestinal stromal tumors. Jiang J; Jin MS; Suo J; Wang YP; He L; Cao XY World J Gastroenterol; 2012 May; 18(20):2569-75. PubMed ID: 22654456 [TBL] [Abstract][Full Text] [Related]
7. E6/E7-P53-POU2F1-CTHRC1 axis promotes cervical cancer metastasis and activates Wnt/PCP pathway. Zhang R; Lu H; Lyu YY; Yang XM; Zhu LY; Yang GD; Jiang PC; Re Y; Song WW; Wang JH; Zhang CC; Gu F; Luo TJ; Wu ZY; Xu CJ Sci Rep; 2017 Mar; 7():44744. PubMed ID: 28303973 [TBL] [Abstract][Full Text] [Related]
8. microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Akçakaya P; Caramuta S; Åhlen J; Ghaderi M; Berglund E; Östman A; Bränström R; Larsson C; Lui WO Br J Cancer; 2014 Nov; 111(11):2091-102. PubMed ID: 25349971 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of CTHRC1 in hepatocellular carcinoma promotes tumor invasion and predicts poor prognosis. Chen YL; Wang TH; Hsu HC; Yuan RH; Jeng YM PLoS One; 2013; 8(7):e70324. PubMed ID: 23922981 [TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors. Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T Digestion; 2013; 87(1):47-52. PubMed ID: 23343969 [TBL] [Abstract][Full Text] [Related]
12. Practical role of mutation analysis for imatinib treatment in patients with advanced gastrointestinal stromal tumors: a meta-analysis. Zhi X; Zhou X; Wang W; Xu Z PLoS One; 2013; 8(11):e79275. PubMed ID: 24223922 [TBL] [Abstract][Full Text] [Related]
13. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China. Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330 [TBL] [Abstract][Full Text] [Related]
14. [Clinical analysis of 156 patients with gastrointestinal stromal tumors receiving imatinib therapy]. Zhang L; Cai M; Deng J; Wang X; Wang B; Liu N; Pan Y; Zhang R; Cui Q; Liang H Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Apr; 17(4):331-4. PubMed ID: 24760639 [TBL] [Abstract][Full Text] [Related]
15. Inactivation of Patched1 in mice leads to development of gastrointestinal stromal-like tumors that express Pdgfrα but not kit. Pelczar P; Zibat A; van Dop WA; Heijmans J; Bleckmann A; Gruber W; Nitzki F; Uhmann A; Guijarro MV; Hernando E; Dittmann K; Wienands J; Dressel R; Wojnowski L; Binder C; Taguchi T; Beissbarth T; Hogendoorn PC; Antonescu CR; Rubin BP; Schulz-Schaeffer W; Aberger F; van den Brink GR; Hahn H Gastroenterology; 2013 Jan; 144(1):134-144.e6. PubMed ID: 23041331 [TBL] [Abstract][Full Text] [Related]
16. CTHRC1 overexpression promotes ectopic endometrial stromal cell proliferation, migration and invasion via activation of the Wnt/β-catenin pathway. Lv Y; Zhang L; Ma J; Fei X; Xu K; Lin J Reprod Biomed Online; 2020 Jan; 40(1):26-32. PubMed ID: 31787549 [TBL] [Abstract][Full Text] [Related]
17. N-glycosylation induces the CTHRC1 protein and drives oral cancer cell migration. Liu G; Sengupta PK; Jamal B; Yang HY; Bouchie MP; Lindner V; Varelas X; Kukuruzinska MA J Biol Chem; 2013 Jul; 288(28):20217-27. PubMed ID: 23703614 [TBL] [Abstract][Full Text] [Related]
18. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hornick JL; Fletcher CD Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861 [TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors. Nishida T; Doi T; Naito Y Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162 [TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal stromal tumours (GISTs): case report and review of the literature. Al-Amri AM; Shawarbi MA; El-Hassan AY; Al-Johi KS Gulf J Oncolog; 2011 Jan; (9):57-60. PubMed ID: 21177210 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]